Stephen Liu/LinkedIn
Jun 3, 2025, 11:20
Stephen V Liu: Randomized Phase 3 Trial of Time of Day of Immunotherapy Infusion
Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:
“This is a major story from ASCO25.
Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm.
Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45!
Impactful, pragmatic, not costly. This should be a bigger story.
Circadian rhythms with potentially major impact on T cell circulation and exhaustion. Do we need to control for time of infusion in studies?
Should we go back and look at results of prior studies by time of infusion? Congratulations to Zhang Yongchang and team!”
Stephen V Liu shared findings from a randomized phase 3 trial presented at ASCO25, demonstrating that the timing of immunotherapy infusion significantly affects outcomes. Early-day infusions showed superior progression-free and overall survival.
More posts featuring Stephen V Liu.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 19, 2025, 07:24
Jul 19, 2025, 07:23
Jul 19, 2025, 07:22
Jul 19, 2025, 07:21
Jul 19, 2025, 02:39
Jul 18, 2025, 21:36
Jul 18, 2025, 21:35